- Stocks
- Pharma & Healthcare
- Vimta Labs
Vimta Labs share price
NSE: VIMTALABSPharma & HealthcareDiagnostics & Research
Vimta Labs at a glance
Vimta Labs (NSE: VIMTALABS) closed at ₹495.55 on 22 Oct 2026, up 2.15% on the day. With a market capitalisation of ₹2,214 Cr, it ranks 1101st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
At its last close the stock traded at 28.5× trailing earnings, against a return on equity of 12.8% in FY24. Over the past year the share price has fallen 28.3%. Its 52-week range is ₹376.05 (30 Mar 2026) to ₹735.00 (3 Nov 2025); the last close is 32.6% below the high. In Q3 FY25, the quarter ended 31 Dec 2024, revenue was ₹90 Cr (+10.1% year on year) and net profit ₹22 Cr (+112.2%), on a consolidated basis. Promoters held 35.67% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹2,214 CrRank 1101 on NSE
- P/E (trailing)
- 28.5×
- Price to book
- 3.08×FY24
- EPS (TTM)
- ₹27.65to Q3 FY25
- ROE
- 12.8%FY24
- ROCE
- 16.4%FY24
- Debt to equity
- 0.06FY24
- Net profit margin
- 12.9%FY24
- Book value / share
- ₹144.20FY24
- Dividend payout
- 10.8%FY24
- 52-week high
- ₹735.003 Nov 2025
- 52-week low
- ₹376.0530 Mar 2026
- 1-year return
- −28.3%
- RSI (14-day)
- 27.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +2.15% | −9.0% | −19.6% | −14.9% | −28.3% |
Vimta Labs quarterly results
| Quarter | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹82 Cr | ₹83 Cr | ₹73 Cr | ₹82 Cr | ₹80 Cr | ₹82 Cr | ₹85 Cr | ₹90 Cr |
| Revenue YoY | +10.4% | +5.5% | −8.1% | +5.6% | −2.6% | −2.1% | +15.4% | +10.1% |
| Net profit | ₹13 Cr | ₹12 Cr | ₹6 Cr | ₹10 Cr | ₹12 Cr | ₹12 Cr | ₹15 Cr | ₹22 Cr |
| Net profit YoY | +7.2% | +1.3% | −52.1% | −1.1% | −2.6% | +0.7% | +140.9% | +112.2% |
| Net margin | 15.5% | 14.6% | 8.6% | 12.4% | 15.5% | 15.0% | 18.0% | 23.9% |
| EPS | ₹5.73 | ₹5.51 | ₹2.85 | ₹4.57 | ₹5.58 | ₹5.54 | ₹6.88 | ₹9.65 |
Vimta Labs financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|---|
| Revenue | ₹181 Cr | ₹211 Cr | ₹278 Cr | ₹318 Cr | ₹318 Cr |
| Operating profit | ₹8 Cr | ₹29 Cr | ₹57 Cr | ₹65 Cr | ₹54 Cr |
| Net profit | ₹7 Cr | ₹21 Cr | ₹41 Cr | ₹48 Cr | ₹41 Cr |
| EPS (₹) | ₹3.00 | ₹10.00 | ₹19.00 | ₹22.00 | ₹19.00 |
| Cash from operations | ₹24 Cr | ₹37 Cr | ₹59 Cr | ₹88 Cr | ₹61 Cr |
| Total debt | ₹5 Cr | ₹14 Cr | ₹13 Cr | ₹10 Cr | ₹9 Cr |
| Shareholders' equity | ₹173 Cr | ₹194 Cr | ₹234 Cr | ₹282 Cr | ₹320 Cr |
Vimta Labs shareholding pattern
| Holder | 14 Jun 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 36.67% | 36.67% | 35.99% | 35.90% | 35.85% | 35.67% |
| Foreign institutions | 3.52% | 3.49% | 4.33% | 4.59% | 4.89% | 4.42% |
| Domestic institutions | 1.42% | 1.42% | 0.87% | 0.11% | 0.14% | 0.37% |
| Non-institutions | 58.39% | 58.42% | 58.80% | 59.41% | 59.12% | 59.55% |
Vimta Labs vs peers
The listed Pharma & Healthcare companies nearest to Vimta Labs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| FREDUNFredun Pharmace | ₹1,376.10 | −0.35% | — | ₹2,276 Cr | 22.5 | — |
| DCALDishman Carbogen Amcis | ₹141.95 | +0.07% | −49.1% | ₹2,226 Cr | 22.8 | — |
| VIMTALABSVimta Labs | ₹495.55 | +2.15% | −28.3% | ₹2,214 Cr | 28.5 | — |
| MEDIASSISTMedi Assist Healthcare Services | ₹291.75 | −0.61% | −46.7% | ₹2,179 Cr | 24.1 | — |
| SYNCOMFSyncom Formulations (India) | ₹22.83 | +3.21% | +38.8% | ₹2,146 Cr | 28.2 | — |
| INDOCOIndoco Remedies | ₹230.55 | +0.74% | −21.9% | ₹2,128 Cr | — | — |
| PANACEABIOPanacea Biotec | ₹335.85 | −1.22% | −24.2% | ₹2,057 Cr | — | — |
Ask anything about Vimta Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against VIMTALABS's own history. Try: “Why has VIMTALABS moved over the last three months?” · “Backtest a 50-day moving-average crossover on VIMTALABS over five years” · “Compare VIMTALABS with FREDUN on margins and valuation”
Frequently asked questions about Vimta Labs
What is the share price of Vimta Labs today?
Vimta Labs (NSE: VIMTALABS) last closed at ₹495.55 on 22 Oct 2026. Its 52-week high is ₹735.00 and its 52-week low is ₹376.05.
What is the market cap of Vimta Labs?
Vimta Labs' market capitalisation is ₹2,214 Cr (₹2,214 Cr) at the 22 Oct 2026 close, ranking 1101st among the NSE companies Pivot tracks.
What is the P/E ratio of Vimta Labs?
Vimta Labs trades at a trailing P/E of 28.5. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 24.1.
What is the ROE and ROCE of Vimta Labs?
Return on equity was 12.8% in FY24 and return on capital employed was 16.4% in FY24 (consolidated figures).
Is Vimta Labs a debt-free company?
No. Vimta Labs' debt-to-equity ratio was 0.06 in FY24, with total debt of ₹9 Cr.
What were Vimta Labs' latest quarterly results?
For Q3 FY25 (quarter ended 31 Dec 2024), Vimta Labs reported revenue of ₹90 Cr, +10.1% year on year, and net profit of ₹22 Cr, +112.2% year on year.
How has Vimta Labs stock performed over the last year?
Vimta Labs' share price has fallen 28.3% over the past year, −14.9% over three months and −19.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Vimta Labs?
As of 30 Jun 2026: promoters 35.67%, foreign institutions 4.42%, domestic institutions 0.37%, non-institutions 59.55%.
Who are Vimta Labs' competitors?
The listed Pharma & Healthcare companies closest to Vimta Labs by market cap are Fredun Pharmace, Dishman Carbogen Amcis, Medi Assist Healthcare Services, Syncom Formulations (India), Indoco Remedies and Panacea Biotec.
Is Vimta Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Vimta Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VIMTALABS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with V · all NSE stocks · this page as text